Bromazepam
Bromazepam belongs to the class of drugs known as Benzodiazepines. The benzodiazepines are a class of medications (drugs) that produce the following effects: sedation and anxiety relief. They are one of the most widely prescribed drugs in the world. Benzodiazepines have essentially replaced the use of barbiturates as the major class of CNS depressants. Bromazepam is an intermediate-acting benzopdiazepine and is primarily used for short-term relief from anxiety and depression. Bromazepam is a pale yellow crystalline powder that is not soluble in water, but is slightly soluble in dilute hydrochloric acid. Bromazepam is 70% protein bound in plasma, and less than 2% of a dose is excreted unchanged in urine.
Bromazepam is metabolized to 3-hydroxybromazepam glucuronide and 2-amino-5-bromo-3-hydroxy-benzoylpyridine glucuronide by the cytochrome P450 system. Bromazepam is one of the benzodiazepine classes that are typically used by drug abusers. Long-term abuse can lead to respiratory depression or, in severe cases, coma. Benzodiazepines are frequently abused drugs and associated especially with heroin and cocaine abusers. Benzodiazepines are only legally available through prescription. Many abusers obtain their supply of these drugs by acquiring several prescriptions from several different physicians, or by forging prescriptions, or by obtaining them illicitly. Alprazolam and diazepam are the two most frequently encountered benzodiazepines on the illicit market today.
Benzodiazepines are rapidly metabolized and excreted into the urine, allowing detection by various analytical methods such as Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS), Immunoassay (IA) screening, and screening spot testing.
Benzodiazepines can elicit the following side effects: amnesia, hostility, irritability, allergic reactions, skin rash, and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, impaired thinking, slow speech, weak and rapid pulse, coma, and possible death.
- Therapeutic monitoring in serum
- Drug abuse evaluation
- Toxicity assessment in serum
- Patient Compliance
Therapeutic concentration: 80 - 150 ng/mL
Toxic concentration: 300 - 400 ng/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- Frozen: 30 days
- J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
- Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303] Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
- Principles of Forensic Toxicology, Fourth Edition. Ed, Barry Levine. AACC Press, Washington DC. Chapter 14, Benzodiazepines, pp. 237-251 (2013).
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
- Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.
- Kaplan, SA, Jack ML, Weinfeld RE, Gloves W, Weissman L, and Cotler S. Biopharmaceutical and Clinical Pharmacokinetic Profile of Bromazepam. J Pharmacokinet Biopharm. 1976; 4(1).